Feasibility and Safety of Geniculate Artery Embolization for Treatment of Mild to Moderate Knee Osteoarthritis

Brief description of study

The purpose of this study is to evaluate the safety and feasibility of genicular artery embolization using EmbozeneTM microspheres for mild-to-moderate knee osteoarthritis (OA) detected on knee x-ray in patients with knee pain resistant to conservative treatment. Embolization is a minimally invasive surgical technique. The purpose of embolization is to prevent blood flow to an area of the body. Embolization of the geniculate artery will be performed using Embozene™ Microspheres. Embozene™ microspheres are embolization material that are approved by the Food and Drug Administration (FDA) for other indications including arteriovenous malformations (AVM) or tangled blood vessels, certain types of tumors, and embolization of arteries in the prostate for treatment of symptomatic benign prostatic hyperplasia (BPH). In this study, Embozene™ microspheres are considered investigational because they are not FDA-approved for embolization of the geniculate artery for the treatment of knee pain in patients with knee osteoarthritis.


Clinical Study Identifier: s19-00370
ClinicalTrials.gov Identifier: NCT04379700
Principal Investigator: Bedros Taslakian.
Other Investigators: William B. Macaulay, Erin Fitzgerald Alaia, Jonathan Samuels.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.